Jones Taff, Adamovicz Jeffrey J, Cyr Sonya L, Bolt Chris R, Bellerose Nathalie, Pitt Louise M, Lowell George H, Burt David S
ID Biomedical Corporation of Quebec, 525 Cartier Blvd West, Laval, Montreal, Que., Canada H7V 3S8.
Vaccine. 2006 Mar 6;24(10):1625-32. doi: 10.1016/j.vaccine.2005.09.052. Epub 2005 Oct 7.
F1-V is a recombinant plague antigen comprising the capsular (F1) and virulence-associated (V) proteins. Given intramuscularly with Alhydrogel, it protects mice against challenge, but is less effective in non-human primates against high-dose aerosolized Yersinia pestis challenge, perhaps because it fails to induce respiratory immunity. Intranasal immunization of mice with F1-V formulated with a Proteosome-based adjuvant (Protollin), elicited high titers of specific IgA in lungs whereas intranasal F1-V alone or intramuscular Alhydrogel-adsorbed F1-V did not. The Protollin-adjuvanted F1-V vaccine also induced high serum titers of specific IgG, comparable to those induced by intramuscular Alhydrogel-adsorbed F1-V. Mice immunized intranasally with Protollin-F1-V were 100% protected against aerosol challenge with 170 LD50 of Y. pestis and 80% against 255 LD50.
F1-V是一种重组鼠疫抗原,由荚膜(F1)蛋白和毒力相关(V)蛋白组成。与氢氧化铝佐剂一起肌肉注射时,它能保护小鼠免受攻击,但在非人类灵长类动物中,对于高剂量雾化鼠疫耶尔森菌攻击的防护效果较差,这可能是因为它未能诱导呼吸道免疫。用基于蛋白酶体的佐剂(Protollin)配制的F1-V对小鼠进行鼻内免疫,可在肺部引发高滴度的特异性IgA,而单独鼻内给予F1-V或肌肉注射用氢氧化铝吸附的F1-V则不会。用Protollin佐剂的F1-V疫苗还能诱导产生高血清滴度的特异性IgG,与肌肉注射用氢氧化铝吸附的F1-V诱导产生的水平相当。用Protollin-F1-V进行鼻内免疫的小鼠,对于170倍半数致死剂量(LD50)的鼠疫耶尔森菌气溶胶攻击有100%的保护作用,对于255倍LD50的攻击有80%的保护作用。